The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Perioperative pembrolizumab for stomach cancer treatment
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, highlights the relevance of the KEYNOTE-585 (NCT03221426) study trialing perioperative pembrolizumab for locally advanced resectable gastric and gastroesophageal junction adenocarcinoma. Many patients require additional therapy following standard chemotherapy and surgery; as PD-1 inhibitors improved survival outcomes in patients with metastatic gastric cancer, pembrolizumab is being investigated in this setting, hopefully with beneficial results once again. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
